…and it’s a minded no. As part of the Highly Specialised Technologies programme, the “Committee requests that the company provides a further explanation of the cost of elosulfase alfa, in the context of development and manufacturing costs, the benefits it provides to people with the condition, and the budget impact on the NHS and Personal Social Services.”
What about NHS patient impact? With no published ICERs and the company’s estimate of life years gained of around 34 being cut to less than 3 in some of the ERG’s analyses, the impact on NHS patients is probably going to be quite high.
